The Problem An average of only 1 in 10,000 drug candidates makes it to market due to ADME-Tox failures. Even those that do, such as Vioxx, can have unforeseen problems. This is because the existing test-tube and cell-based screens being used to identify these compounds do not predict the deliverability, stability, specificity or metabolic issues encountered within the human body. Consequently tens of years, millions of dollars and numerous animal and human lives are wasted.

The Solution InDanio's genetically engineered Zebrafish lines provide a "highest human homology" in vivo HTS model, where not only are the binding and potency of lead compounds immediately identified, but target and tissue specificity, as well as vital organ accumulation, can for the first time be immediately realized. A successful in vivo vertebrate screening model can